Cidara Therapeutics, Inc.

DB:20D0 Stock Report

Market Cap: €286.3m

Cidara Therapeutics Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

Jeff Stein

Chief executive officer

US$1.6m

Total compensation

CEO salary percentage38.1%
CEO tenure11yrs
CEO ownership0.7%
Management average tenure3.7yrs
Board average tenure4yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Jeff Stein's remuneration changed compared to Cidara Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$124m

Jun 30 2024n/an/a

-US$112m

Mar 31 2024n/an/a

-US$24m

Dec 31 2023US$2mUS$594k

-US$25m

Sep 30 2023n/an/a

-US$34m

Jun 30 2023n/an/a

-US$18m

Mar 31 2023n/an/a

-US$22m

Dec 31 2022US$1mUS$566k

-US$22m

Sep 30 2022n/an/a

-US$33m

Jun 30 2022n/an/a

-US$63m

Mar 31 2022n/an/a

-US$44m

Dec 31 2021US$2mUS$566k

-US$42m

Sep 30 2021n/an/a

-US$47m

Jun 30 2021n/an/a

-US$47m

Mar 31 2021n/an/a

-US$74m

Dec 31 2020US$1mUS$542k

-US$75m

Sep 30 2020n/an/a

-US$67m

Jun 30 2020n/an/a

-US$47m

Mar 31 2020n/an/a

-US$42m

Dec 31 2019US$1mUS$526k

-US$41m

Sep 30 2019n/an/a

-US$39m

Jun 30 2019n/an/a

-US$56m

Mar 31 2019n/an/a

-US$69m

Dec 31 2018US$1mUS$501k

-US$69m

Compensation vs Market: Jeff's total compensation ($USD1.56M) is above average for companies of similar size in the German market ($USD837.57K).

Compensation vs Earnings: Jeff's compensation has increased whilst the company is unprofitable.

CEO

Jeff Stein (69 yo)

11yrs

Tenure

US$1,558,544

Compensation

Dr. Jeffrey L. Stein, Ph D., also known as Jeff, has been the Chief Executive Officer, President and Executive Director of Cidara Therapeutics, Inc. since January 2014. Dr. Stein served as Principal Financ...

Leadership Team

NamePositionTenureCompensationOwnership
Jeffrey Stein
President11yrsUS$1.56m0.67%
€ 1.9m
Shane Ward
COO & Corporate Secretary3.4yrsUS$929.86k0.047%
€ 134.5k
Taylor Sandison
Chief Medical Officer8.3yrsUS$884.09k0.12%
€ 335.0k
Kevin Forrest
Founder & Chief Strategy Officerno dataUS$613.24kno data
Preetam Shah
CFO & Principal Accounting Officer3.3yrsUS$683.71k0.069%
€ 196.7k
Allison Lewis
Senior Vice President of People & Culture4yrsno datano data
Leslie Tari
Chief Scientific Officer5.8yrsUS$1.39m0.077%
€ 220.5k
Nicole Davarpanah
Senior Vice President of Translational Research & Development1.4yrsno datano data
Jim Beitel
Chief Business Officerless than a yearno datano data

3.7yrs

Average Tenure

52yo

Average Age

Experienced Management: 20D0's management team is considered experienced (3.7 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Jeffrey Stein
President11yrsUS$1.56m0.67%
€ 1.9m
Daniel Burgess
Independent Chairman of the Board10.8yrsUS$126.84k0.0014%
€ 3.9k
Theodore Schroeder
Independent Director10.8yrsUS$98.84k0%
€ 0
Frederick Hayden
Member of the Scientific Advisory Board4.5yrsno datano data
Bonnie Bassler
Independent Director4yrsUS$86.84k0.00014%
€ 400.8
Carin Canale-Theakston
Independent Director4yrsUS$82.34k0%
€ 0
Chrysa Mineo
Independent Director6.8yrsUS$91.34k0%
€ 0
Ryan Spencer
Independent Directorless than a yearno datano data
James Merson
Independent Directorless than a yearno datano data
Laura Tadvalkar
Independent Directorless than a yearno datano data
Mario Barro
Member of Scientific Advisory Boardless than a yearno datano data
Philip Krause
Member of Scientific Advisory Boardless than a yearno datano data

4.0yrs

Average Tenure

62yo

Average Age

Experienced Board: 20D0's board of directors are considered experienced (4 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/08 03:26
End of Day Share Price 2025/01/08 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Cidara Therapeutics, Inc. is covered by 14 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Timothy ChiangBTIG
Chiara RussoCantor Fitzgerald & Co.
Louise ChenCantor Fitzgerald & Co.